Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer

Zhejiang University

Status and phase: Completed; Phase 2

Conditions: Colorectal Cancer

Treatments: Drug: Combinations

Study type: Interventional

Funder types: Other

Identifiers

NCT05414461

CombiImmuno mCRC

Details and patient eligibility

About

Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.

Enrollment: 97 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment
• patients with identified genomic status

Exclusion criteria

• patients who received immune monotherapy
• patients who stopped treatment for any reason without identified response assessment.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

97 participants in 1 patient group

Combination treatment

Experimental group

Description:

PD-1 inhibitor-based combination treatment

Treatment:

Drug: Combinations